| Vaxelis 0.5 ml, Injektionssuspension - | | 66940001 | | Future Health Pharma GmbH | | Vaxelis 0.5 ml, Injektionssuspension | | 28.08.2019 | | | | | 28.08.2019 | | Diphtherie-Tetanus-Pertussis-Poliomyelitis-Haemophilus-influenzae-B-Hepatitis-B (J07CA09) | | | | WHO-DDD | | | | 08.08. | | | | 08.08. | | | | B | | | | Ja | | | | FI | | | | 51.14 | | Ja | | | | | | | | | 10% | | 75.20 | | FB | | | | 7680669400019 | | Impfstoffe | | 7750054 | | |
| | Zusammensetzung | | polysaccharida haemophili influenzae typus B conjugata cum proteino neisseriae meningitidis B 53 µg corresp. polysaccharida haemophili influenzae typus B 3 µg et neisseria meningitidis B outer membrane protein complex 50 µg, hepatitidis B viri antigenum ADNr 10 µg, toxoidum pertussis 20 µg, haemagglutininum filamentosum 20 µg, pertactinum 3 µg, fimbriae Typ 2 und 3 5 µg, toxoidum diphtheriae min. 20 U.I., toxoidum tetani min. 40 U.I., virus poliomyelitis typus 1 inactivatus (Mahoney) 40 U., virus poliomyelitis typus 2 inactivatus (MEF-1) 8 U., virus poliomyelitis typus 3 inactivatus (Saukett) 32 U., aluminium ut aluminii phosphas et aluminii hydroxyphosphas sulfas amorphus, natrii phosphates, acidum hydrochloridum q.s. ad pH, natrii hydroxidum q.s. ad pH, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml corresp. natrium 1.95 mg, residui: glutaralum, formaldehydum, neomycinum, streptomycinum, polymyxinum B, albuminum seri bovis, aluminii thiocyanas, faecis proteina. | | Packungsbestandteile | | Injektionssuspension | | | | | | | | Wirkstoffe | Stärke |
|---|
| Haemagglutininum Filamentosum | 20 µg | | Hepatitidis b viri Antigenum Adnr | 10 µg | | Pertactin | 3 µg | | Polysaccharida Haemophili Influenzae Typus b Conjugata cum Proteino Neisseriae Meningitidis B | 53 µg entspricht Polysaccharida Haemophili Influenzae Typus B 3 µg | | Toxoidum Diphtheriae | 20 UI | | Toxoidum Pertussis | 20 µg | | Toxoidum Tetani | 40 UI | | Virus Poliomyelitis Typus 1 Inactivatus (Mahoney) | 40 U | | Virus Poliomyelitis Typus 2 Inactivatus (Mef1) | 8 U | | Virus Poliomyelitis Typus 3 Inactivatus (Saukett) | 32 U |
| | BAG: Wirkstoffe | Stärke |
|---|
| Fimbriae typ 2+3 | 5 mcg | | Haemagglutinium Filamentosum (B. Pertussis) | 20 mcg | | Haemophilus Influenzae b Polysaccharida (Prp) | 3 mcg | | Pertactinum (B. Pertussis) | 3 mcg | | Toxoidum Pertussis | 20 mcg | | Vaccinum Diphtheriae Adsorbatum | 20 UI | | Vaccinum Hepatitidis b (Adnr) Hbsag | 10 mcg | | Vaccinum Tetani Adsorbatum | 40 UI | | Virus Poliomyelitis Typus 1 Inactivatum (Mahoney) | 40 U | | Virus Poliomyelitis Typus 2 Inactivatum (Mef1) | 8 U | | Virus Poliomyelitis Typus 3 Inactivatum (Saukett) | 32 U |
| | | | Hilfsstoffe | Stärke |
|---|
| Acidum Hydrochloridum | | | Aluminii Hydroxyphosphas Sulfas Amorphus | | | Alumin | | | Fimbriae Typ | 2 | | Natrii Phosphates | | | Neisseria Meningitidis b Outer Membrane Protein Complex | 50 µg | | Und 3 | 5 µg |
| |
| | Quelle | | Datum des Datenimports : 06.02.2024
Swissmedic-Registration :
Sequenz :
Präparatname :
Zulassungsinhaber: :
Produktgruppe :
Index Therapeuticus (BSV) :
Heilmittelcode :
Registrierungsdatum :
Gültig bis :
Packungsnummer :
Packungsgrösse :
Handelsform/Einheit :
Abgabekategorie :
Wirkstoffe :
Zusammensetzung :
| |
|
|
